Anti-Human IL 12/23 (Briakinumab) Dylight 488 (IVMB0511)
- SKU:
- IVMB0511
Frequently bought together:
Description
| Product Name: | Anti-Human IL 12/23 (Briakinumab) Dylight 488 |
| SKU: | IVMB0511 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | ABT-874 |
| Target: | IL-12/IL-23 p40 |
| Isotype: | Human IgG1λ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | FA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23 |
| Product Concentration: | 0.2 mg/ml |
| Excitation Laser: | Blue Laser (493 nm) |
| Immunogen: | This antibody was produced by phage display technology. |
| Applications and Recommended Usage: | FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
| Antigen Distribution: | IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes. |
| Formulation: | This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only. |
| Additional Applications Reported In Literature: | FA |
| Additional Reported Applications For Relevant Conjugates: | BNWBELISAIP |
Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
